Monday, November 05, 2012
(UK) Oncologists' views about the treatments and care associated with advanced ovarian cancer
Oncologists' views about the treatments and care associated with advanced ovarian cancer
Background
Ovarian cancer treatment depends on histological type, grade and stage of the tumour and general performance status of the patient. Patients may have different expectations about treatment and place different values on outcomes from those of healthcare professionals.Method
We used an online survey to examine: how UK oncologists manage women with advanced ovarian cancer; available anti-cancer treatments used in practice; oncologists' views on patients' worst symptoms and available supportive interventions. In addition, we are currently interviewing 200 patients about their experiences of treatment and management of their disease in the ADVOCATE study (Advanced Ovarian Cancer: Care & Treatment Experiences).Results
66 oncologists (44 medical; 22 clinical) completed the survey between October and December 2011. 51 worked in a designated gynaecological cancer centre, 54 were NHS Trust clinicians; 59 trialists and 52 respondents treated >31 advanced disease patients annually. Abdominal pain/swelling was ranked the most common presenting feature (n=46). Carboplatin with paclitaxel (n=56) was the usual 1st line treatment and symptomatic disease progression was main trigger for changes in management. Carboplatin with paclitaxel was the most used for 2nd line (n=39) and subsequent treatments in partially/ platinum sensitive patients (n=25); liposomal doxirubicin for platinum resistant/refractory disease (n=42). The majority (n= 63) conducted routine clinical follow-up, measuring CA125 levels regularly (n=43). Bevacizumab was rarely offered as maintenance therapy (n=3), mainly as not NICE approved (n=49). The minimum PFS gains most oncologists (24/50) felt worthwhile for maintenance therapy was 4-5 months but (26/50) believed patients would consider 3-4 months worthwhile. For OS, 36/60 oncologists indicated 3-4mths as worthwhile; 25/60 felt 1-2mths would be their patients' choice.Conclusion
These results reflect current practice of trial-active oncologists when treating advanced ovarian cancer. Results from patients' experiences in the ADVOCATE study, will reveal the impact of these treatments and patients' unmet supportive care needs.Introduction: Ovarian cancer - Turning knowledge into treatment
Introduction: Ovarian cancer - Turning knowledge into treatment
"In the past five years, there has been a huge advance in our understanding of the biology of the group of diseases collectively known as ovarian cancer. However, these advances have yet to translate themselves into improved outcomes for patients: Throughout the world, survival rates have improved little since the introduction of platinum-based chemotherapy thirty years ago. In the UK, for example, five year survival rates have increased by less than 4% since 1995.
One of the key changes is the realisation that ovarian cancer is not one disease, but many, each with its own distinct aetiology and molecular biology, and collectively linked merely by a shared anatomical location. This realisation is starting to manifest itself in changes to clinical trial design, as subtype-specific studies emerge, utilising novel agents targeting subtype-specific pathways. Further refinement will require international collaboration, especially in the rare subtypes, as well as improved preclinical modelling: We still await a reliable and realistic transgenic model of high grade serous disease, whilst many of the cell lines in widespread use are of uncertain provenance.....
Performance characteristics of ultrasound screening in the United Kingdom collaborative trial of ovarian cancer screening (UKCTOCS)
Performance characteristics of ultrasound screening in the United Kingdom collaborative trial of ovarian cancer screening (UKCTOCS)
Conclusion
While specificity of transvaginal ultrasound screening was high,
sensitivity was higher for primary ovarian/tubal cancers than for
invasive epithelial cancers alone. While 15 operations were done overall
for each primary ovarian/tubal cancer detected, 25 were done per
primary invasive epithelial cancer. The mortality impact of screening is
awaited in 2014.
NCRI Cancer Conference - Abstract Information
NCRI Cancer Conference - Abstract Information
Search Abstracts
Please enter one or more keywords to search the abstracts.
Note that '*' and '?' wildcards are supported.
Search results for: ovarian
56 results found.
The first UK multicentre figures showing that one in five women having major gynaecological cancer surgery have some sort of complication
"The initial findings of the UK Gynaecological Oncology Surgical Outcomes and Complications (UKGOSOC) audit also reveal that one in 30 women experience a serious complication, which may need another operation or procedure.....
IKK-ε Coordinates Invasion and Metastasis of Ovarian Cancer
IKK-ε Coordinates Invasion and Metastasis of Ovarian Cancer
Abstract
Inhibitor of IÎşB kinases (IKK) are key regulators of NF-ÎşB signaling. Three IKK isoforms—α, β, and ε—have been linked to oncogenesis, yet the precise components of NF-ÎşB signaling in ovarian cancer have not yet been dissected. We surveyed 120 ovarian cancer specimens for IKK-ε expression. Notably, cytoplasmic expression was elevated in metastatic lesions relative to primary tumors (P = 0.03). Therefore, we hypothesized that IKK-ε drives ovarian cancer metastasis. IKK-ε was identified previously as a breast cancer oncogene and was associated with poor clinical outcome in ovarian cancer.....A Phase II, Randomized, Placebo-Controlled Study of Vismodegib as Maintenance Therapy in Patients with Ovarian Cancer in Second or Third Complete Remission
A Phase II, Randomized, Placebo-Controlled Study of Vismodegib as Maintenance Therapy in Patients with Ovarian Cancer in Second or Third Complete Remission
Conclusions: In this study, the sought magnitude of increase in PFS was not achieved for vismodegib maintenance versus placebo in patients with ovarian cancer in second or third CR. The frequency of Hedgehog ligand expression was lower than expected.
Sunday, November 04, 2012
Egypt - Retrospective analysis evaluating ovarian cancer cases presented at the clinical oncology department
Retrospective analysis evaluating ovarian cancer cases presented at the clinical oncology department, Alexandria University
Conclusion
The age
incidence of ovarian cancer in our patients is 10 years younger than
that seen in Western countries. EOC constitutes the majority among all
ovarian cancer cases, followed by border line tumors. Papillary serous
cystadenocarcinoma predominates other types of EOC. The response rate of
EOC to first line chemotherapy was high but the progression free
survival was lower than that seen in the literature.
Saturday, November 03, 2012
urinary system/surgical management UUTTCC (of interest to Lynch Syndrome patients)
(abstract) Surgical management for upper urinary tract transitional cell carcinoma
http://commons.wikimedia.org/wiki/File%3AUrinary_system.svg
Description
English: Urinary system
By Jordi March i Nogué [1] (Own work) [CC-BY-SA-3.0 (http://creativecommons.org/licenses/by-sa/3.0) or GFDL (http://www.gnu.org/copyleft/fdl.html)], via Wikimedia Commons
- Urinary system
- Kidney
- Renal pelvis
- Ureter
- Urinary bladder
- Urethra (Left side with frontal section)
- Adrenal gland
- Renal artery and vein
- Inferior vena cava
- Abdominal aorta
- Common iliac artery and vein
- Liver
- Large intestine
- Pelvis
An unmeasured harm of screening: a physician's perspective
An unmeasured harm of screening: a physician's perspective
"...Such examples should not be confined to the pages of medical journals. Consumers need to read about these as well.
Our 6.5 year experience in reviewing health care news stories on HealthNewsReview.org shows a clear and overwhelming pattern of messages that emphasize/exaggerate the potential benefits of medical interventions and minimize or totally ignore potential harms."
Abstract OBJECTIVE: To investigate the clinical characteristics, diagnosis, treatment and prognosis of malignant ovarian germ cell tumors (MOGCT) with lung metastasis.
Abstract
OBJECTIVE:
To investigate the clinical characteristics, diagnosis, treatment and prognosis of malignant ovarian germ cell tumors (MOGCT) with lung metastasis.Serous epithelium, serious interpretations - 2012 - Cancer Cytopathology
Serous epithelium, serious interpretations - 2012 - Cancer Cytopathology
" The use of peritoneal washings (PWs) for the assessment of gynecologic neoplastic disease has an established history, and has been used in the settings of ovarian, endometrial, cervical, and nongynecologic neoplasms.1, 2 Although numerous publications have heralded the cytomorphologic features of ovarian carcinoma in PWs, fewer reports have addressed the features of borderline tumors in these specimens; some have shown that the examination of PWs is an effective means with which to identify peritoneal extension of ovarian tumors of low malignant potential.3 The identification of tumors of borderline malignancy is inherently more challenging, taking the interpretation of cytologic specimens to another level of difficulty.....
Ameridose - 2nd Pharmacy Recalls Thousands of Drugs - eMedicineHealth
2nd Pharmacy Recalls Thousands of Drugs - eMedicineHealth
"... Ameridose sold more than 2,200 sterile mixed IV solutions and prefilled oral syringes. It offered products ranging from delivery-room medications to neonatal and pediatric drugs to pain pumps for cancer patients. Product lines range from antibiotics to anesthetics to tranquilizers...."
"The FDA says Ameridose will post a list of all recalled medications on its web site. Customers with Ameridose products should contact Ameridose at 888-820-0622 for instructions on how to return products to Ameridose.
The FDA says it recommended the recall "out of an abundance of caution" after its ongoing inspection "raised concerns about a lack of sterility assurance" for Ameridose products.
Despite the recall, the FDA is not asking doctors, clinics, and hospitals that used Ameridose products to warn patients that received the medications. It's simply asking Ameridose customers to stop using the drugs and to return them to the company....
Friday, November 02, 2012
Cancer Screening and Treatment in Women: Recent Findings: Program Brief
Cancer Screening and Treatment in Women: Recent Findings: Program Brief
Program BriefThis program brief summarizes findings from Agency for Healthcare Research and Quality (AHRQ)-supported research projects focused on cancer in women published January 2008 through December 2011. " Data from the National Cancer Institute indicate that 1 in 72 women born today will be diagnosed with cancer of the ovary at some point in their lives. Ovarian cancer occurs in white women (12.6 cases per 100,000 women) more often than in women of other races (11.2 Hispanic, 9.3 black, 9.2 Asian/Pacific Islander, and 9.0 American Indian/Alaska Native). According to the Centers for Disease Control and Prevention, 21,204 women were diagnosed with ovarian cancer in 2008, and 14,362 women died from the disease. The overall 5-year survival rate for women diagnosed with ovarian cancer was 44 percent in 2008. More than 90 percent of those diagnosed with localized ovarian cancer survived for 5 years or more, compared with just 27 percent of those whose cancer had spread to distant organs." |
Subscribe to:
Posts
(
Atom
)
